Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Early baldness and little chest hair may indicate higher prostate cancer risk.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Certain genetic markers may increase or decrease prostate cancer risk.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Men with certain types of baldness at age 45 may have a higher risk of colon cancer and colorectal adenoma.

Certain gene combinations may affect prostate cancer risk, and GSTP1 methylation is linked to tumor aggressiveness.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Finasteride and dutasteride may lower melanoma risk, with teenage acne possibly indicating higher risk.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Male pattern baldness may be linked to prostate cancer risk.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Prostate cancer screening doesn't significantly reduce death rates and has risks like overdiagnosis and side effects.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.